Therefore EGFR tyrosine kinase inhibitors would be a reasonable therapeutic option to adenosquamous lung carcinoma patients due to the relatively high frequency of EGFR mutations in this cohort. This evidence concerns the gene EGFR and adenosquamous lung carcinoma.